Business & Finance
Cardax reports Q1 2018 revenues
10 May 2018 -

Cardax Inc. (OTCQB: CDXI), a company that devotes substantially all of its efforts to developing and commercializing dietary supplements and pharmaceuticals, has reported its revenues for the first quarter of 2018, it was reported yesterday.

Revenues from sales of ZanthoSyn®, its premium astaxanthin dietary supplement for inflammatory health and longevity, increased almost three-fold from USD107,990 in the first quarter of 2017 to USD313,310 in the first quarter of 2018.

ZanthoSyn was the top selling product at General Nutrition Corporation stores in Hawaii for the second consecutive quarter.